Tilray Brands, Inc. Litigation Settlement, Expense
Tilray Brands, Inc. (TLRY) reported Litigation Settlement, Expense of $3.90 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LitigationSettlementExpense · last filed 2026-07-28
- Tilray Brands, Inc. litigation settlement, expense for the quarter ending 2026-05-31 was $1.41M, a 88.38% decline year-over-year.
- Tilray Brands, Inc. litigation settlement, expense for the quarter ending 2026-02-28 was $621.00K, a 77.48% decline year-over-year.
- Tilray Brands, Inc. litigation settlement, expense for the quarter ending 2025-11-30 was $869.00K, a 3.55% decline year-over-year.
- Tilray Brands, Inc. litigation settlement, expense for the quarter ending 2025-08-31 was $1.01M, a 36.87% decline year-over-year.
- Tilray Brands, Inc. litigation settlement, expense for fiscal 2026 was $3.90M, a 77.51% decline from fiscal 2025.
- Tilray Brands, Inc. litigation settlement, expense for fiscal 2025 was $17.35M, a 110.24% increase from fiscal 2024.
- Tilray Brands, Inc. litigation settlement, expense for fiscal 2024 was $8.25M.
- Tilray Brands, Inc. litigation settlement, expense for fiscal 2023 was -$505.00K, a 103.06% decline from fiscal 2022.
| Period end | Litigation Settlement, Expense 3 month | Litigation Settlement, Expense 6 month | Litigation Settlement, Expense 9 month | Litigation Settlement, Expense 12 month |
|---|---|---|---|---|
| 2026-05-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-28 | $2.03M derived: sum of 2 quarters · filed 2026-07-28 | $2.90M derived: sum of 3 quarters · filed 2026-07-28 | $3.90M 10-K · filed 2026-07-28 |
| 2026-02-28 | $621.00K 10-Q · filed 2026-04-01 | $1.49M derived: sum of 2 quarters · filed 2026-04-01 | $2.50M 10-Q · filed 2026-04-01 | $14.59M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-11-30 | $869.00K 10-Q · filed 2026-01-08 | $1.88M 10-Q · filed 2026-01-08 | $13.97M derived: sum of 3 quarters · filed 2026-07-28 | $16.73M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-08-31 | $1.01M 10-Q · filed 2025-10-09 | $13.10M derived: sum of 2 quarters · filed 2026-07-28 | $15.86M derived: sum of 3 quarters · filed 2026-07-28 | $16.76M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-05-31 | $12.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-28 | $14.85M derived: sum of 2 quarters · filed 2026-07-28 | $15.75M derived: sum of 3 quarters · filed 2026-07-28 | $17.35M 10-K · filed 2026-07-28 |
| 2025-02-28 | $2.76M 10-Q · filed 2026-04-01 | $3.66M derived: sum of 2 quarters · filed 2026-04-01 | $5.25M 10-Q · filed 2026-04-01 | $5.07M derived: sum of 4 quarters · filed 2026-07-28 |
| 2024-11-30 | $901.00K 10-Q · filed 2026-01-08 | $2.50M 10-Q · filed 2026-01-08 | $2.31M derived: sum of 3 quarters · filed 2026-07-28 | $5.67M derived: sum of 4 quarters · filed 2026-07-28 |
| 2024-08-31 | $1.59M 10-Q · filed 2025-10-09 | $1.41M derived: sum of 2 quarters · filed 2026-07-28 | $4.77M derived: sum of 3 quarters · filed 2026-07-28 | $7.81M derived: sum of 4 quarters · filed 2026-07-28 |
| 2024-05-31 | -$188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-28 | $3.17M derived: sum of 2 quarters · filed 2026-07-28 | $6.22M derived: sum of 3 quarters · filed 2026-07-28 | $8.25M 10-K · filed 2026-07-28 |
| 2024-02-29 | $3.36M 10-Q · filed 2025-04-08 | $6.41M derived: sum of 2 quarters · filed 2025-04-08 | $8.44M 10-Q · filed 2025-04-08 | $9.90M derived: sum of 4 quarters · filed 2025-07-29 |
| 2023-11-30 | $3.04M 10-Q · filed 2025-01-10 | $5.08M 10-Q · filed 2025-01-10 | $6.54M derived: sum of 3 quarters · filed 2025-07-29 | $1.31M derived: sum of 4 quarters · filed 2025-07-29 |
| 2023-08-31 | $2.03M 10-Q · filed 2024-10-10 | $3.50M derived: sum of 2 quarters · filed 2025-07-29 | -$1.73M derived: sum of 3 quarters · filed 2025-07-29 | $1.08M derived: sum of 4 quarters · filed 2025-07-29 |
| 2023-05-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-29 | -$3.77M derived: sum of 2 quarters · filed 2025-07-29 | -$950.00K derived: sum of 3 quarters · filed 2025-07-29 | -$505.00K 10-K · filed 2025-07-29 |
| 2023-02-28 | -$5.23M 10-Q · filed 2024-04-09 | -$2.42M derived: sum of 2 quarters · filed 2024-04-09 | -$1.97M 10-Q · filed 2024-04-09 | $8.06M derived: sum of 4 quarters · filed 2024-10-10 |
| 2022-11-30 | $2.81M 10-Q · filed 2024-01-09 | $3.26M 10-Q · filed 2024-01-09 | $13.29M derived: sum of 3 quarters · filed 2024-10-10 | $17.50M derived: sum of 4 quarters · filed 2024-10-10 |
| 2022-08-31 | $445.00K 10-Q · filed 2024-10-10 | $10.47M derived: sum of 2 quarters · filed 2024-10-10 | $14.69M derived: sum of 3 quarters · filed 2024-10-10 | $15.77M derived: sum of 4 quarters · filed 2024-10-10 |
| 2022-05-31 | $10.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $14.24M derived: sum of 2 quarters · filed 2024-07-30 | $15.32M derived: sum of 3 quarters · filed 2024-07-30 | $16.52M 10-K · filed 2024-07-30 |
| 2022-02-28 | $4.21M 10-Q · filed 2023-04-10 | $5.29M derived: sum of 2 quarters · filed 2023-04-10 | $6.49M 10-Q · filed 2023-04-10 | |
| 2021-11-30 | $1.08M 10-Q · filed 2023-01-09 | $2.27M 10-Q · filed 2023-01-09 | ||
| 2021-08-31 | $1.19M 10-Q · filed 2022-10-07 | |||
| 2021-05-31 | $3.25M 10-K · filed 2023-07-26 | |||
| 2021-03-31 | $45.00M 10-Q · filed 2021-05-10 | |||
| 2020-05-31 | $1.83M 10-K · filed 2022-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |